EP1084236A4 - Novel adenoviral vectors for gene therapy - Google Patents

Novel adenoviral vectors for gene therapy

Info

Publication number
EP1084236A4
EP1084236A4 EP99927250A EP99927250A EP1084236A4 EP 1084236 A4 EP1084236 A4 EP 1084236A4 EP 99927250 A EP99927250 A EP 99927250A EP 99927250 A EP99927250 A EP 99927250A EP 1084236 A4 EP1084236 A4 EP 1084236A4
Authority
EP
European Patent Office
Prior art keywords
gene therapy
adenoviral vectors
novel adenoviral
novel
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99927250A
Other languages
German (de)
French (fr)
Other versions
EP1084236A1 (en
Inventor
Manal A Morsy
Volker Sandig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1084236A1 publication Critical patent/EP1084236A1/en
Publication of EP1084236A4 publication Critical patent/EP1084236A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
EP99927250A 1998-06-09 1999-06-04 Novel adenoviral vectors for gene therapy Withdrawn EP1084236A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8860598P 1998-06-09 1998-06-09
US88605P 1998-06-09
US9725898P 1998-08-20 1998-08-20
US97258P 1998-08-20
PCT/US1999/012548 WO1999064577A1 (en) 1998-06-09 1999-06-04 Novel adenoviral vectors for gene therapy

Publications (2)

Publication Number Publication Date
EP1084236A1 EP1084236A1 (en) 2001-03-21
EP1084236A4 true EP1084236A4 (en) 2003-04-02

Family

ID=26778857

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99927250A Withdrawn EP1084236A4 (en) 1998-06-09 1999-06-04 Novel adenoviral vectors for gene therapy

Country Status (4)

Country Link
EP (1) EP1084236A4 (en)
JP (1) JP2002517234A (en)
CA (1) CA2329947A1 (en)
WO (1) WO1999064577A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1302403B1 (en) * 1998-11-06 2000-09-05 Angeletti P Ist Richerche Bio CELLS FOR THE PRODUCTION OF DEFECTIVE ADENOVIRAL VECTORS, METHOD FOR THEIR PREPARATION AND USE.
ES2292271B1 (en) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. AN ADENOVIRUS-ALFAVIRUS HYBRID VECTOR FOR THE EFFECTIVE ADMINISTRATION AND EXPRESSION OF THERAPEUTIC GENES IN TUMOR CELLS.
CA3104113A1 (en) * 2018-06-22 2019-12-26 Asklepios Biopharmaceutical, Inc. Vectors for gene delivery that persist within cells
CN110577968A (en) * 2019-08-21 2019-12-17 湖州中科湖兴生物科技有限公司 Construction and production method of novel adenovirus vector

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012649A2 (en) * 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0954579A1 (en) * 1996-06-20 1999-11-10 Merck & Co., Inc. Gene therapy for obesity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012649A2 (en) * 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9964577A1 *

Also Published As

Publication number Publication date
EP1084236A1 (en) 2001-03-21
JP2002517234A (en) 2002-06-18
WO1999064577A1 (en) 1999-12-16
CA2329947A1 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
EP1109896A4 (en) Adenovirus formulations for gene therapy
AU3635899A (en) Recombinant adenovirus gene transfer vector
IL207404A0 (en) Novel colloid synthetic vectors for gene therapy
AU3358999A (en) Chimeric adenoviral vectors for targeted gene delivery
AU2001257532A1 (en) Adenoviral vectors for tumor specific gene expression and uses thereof
AU3169495A (en) Gene therapy for restenosis using an adenoviral vector
GB9922283D0 (en) Adenoviral vectors
HUP0104046A3 (en) Adenovirus-mediated gene therapy
EP1071472A4 (en) Peptides for efficient gene transfer
GB2322131B (en) Improved retroviral vectors for gene therapy
HUP9902150A3 (en) Recombinant adenoviral vectors for human tumour gene therapy
AU4099699A (en) Improved vectors
EP1084236A4 (en) Novel adenoviral vectors for gene therapy
IL148805A0 (en) Gene transfer vectors
AU2145300A (en) Adenoviral vectors
AU3036197A (en) Adenovirus vectors for gene therapy
EP1038957A4 (en) Tsa305 gene
GB0025890D0 (en) Gene therapy
GB0008966D0 (en) Vectors for gene therapy
GB9900009D0 (en) Gene therapy
GB0406539D0 (en) Gene therapy
GB9724828D0 (en) Gene
GB9804178D0 (en) Tumour suppressor gene
GB9816775D0 (en) Herpesviral vectors for gene delivery
GB9819721D0 (en) Novel gene

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010109

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030213

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 15/85 B

Ipc: 7A 61K 48/00 B

Ipc: 7C 12N 5/00 B

Ipc: 7C 12N 15/00 A

17Q First examination report despatched

Effective date: 20030624

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040504